{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:54:43Z","timestamp":1761598483383,"version":"3.32.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jneuroim.2022.578014","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T06:41:00Z","timestamp":1672641660000},"page":"578014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis"],"prefix":"10.1016","volume":"375","author":[{"given":"Hiroyuki","family":"Akamine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2022.578014_bb0005","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1084\/jem.190.8.1123","article-title":"In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines","volume":"190","author":"Ansel","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000945","article-title":"Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0015","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.3390\/cancers13123034","article-title":"Soluble programmed death Ligand-1 (sPD-L1): a Pool of circulating proteins implicated in health and diseases","volume":"13","author":"Bailly","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrrheum.2009.77","article-title":"Autoimmunity: CTLA-4: a key protein in autoimmunity","volume":"5","author":"Bayry","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0030","doi-asserted-by":"crossref","first-page":"E1142","DOI":"10.3390\/ijms20051142","article-title":"Context-dependent effect of glucocorticoids on the proliferation, differentiation, and apoptosis of regulatory T cells: a review of the empirical evidence and clinical applications","volume":"20","author":"Cari","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.578014_bb0045","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/ana.20577","article-title":"A CTLA4high genotype is associated with myasthenia gravis in thymoma patients","volume":"58","author":"Chuang","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12264-019-00344-1","article-title":"Enhancement of T follicular helper cell-mediated humoral immunity Reponses during development of experimental autoimmune myasthenia gravis","volume":"35","author":"Cui","year":"2019","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12884","article-title":"Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: association with activity and severity","volume":"92","author":"Du","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0065","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0070","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3389\/fimmu.2018.01637","article-title":"T follicular helper cells in autoimmune disorders","volume":"9","author":"Gensous","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0075","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: production, function and biological significance","volume":"6","author":"Gu","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0085","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/0961203320916517","article-title":"Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity","volume":"29","author":"Hirahara","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0090","doi-asserted-by":"crossref","first-page":"21785","DOI":"10.18632\/oncotarget.4798","article-title":"Regulation of T follicular helper cells by ICOS","volume":"6","author":"Hutloff","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jneuroim.2018.09.012","article-title":"Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis","volume":"325","author":"Iwasa","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0105","first-page":"17","article-title":"Role of PD-1 in regulating T-cell immunity","volume":"350","author":"Jin","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.767466","article-title":"Differential role of PD-1 expressed by various immune and tumor cells in the tumor immune microenvironment: expression, function, therapeutic efficacy, and resistance to Cancer immunotherapy","volume":"9","author":"Kim","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0115","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.immuni.2011.06.007","article-title":"A fine romance: T follicular helper cells and B cells","volume":"34","author":"King","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1146\/annurev.immunol.26.021607.090344","article-title":"T follicular helper (TFH) cells in normal and dysregulated immune responses","volume":"26","author":"King","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0125","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/eji.200635978","article-title":"Contribution of the PD-1 ligands\/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation","volume":"36","author":"Kuipers","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10072-013-1460-3","article-title":"Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis","volume":"35","author":"Li","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/sji.12509","article-title":"Serum sPD-L1, upregulated in Sepsis, may reflect disease severity and clinical outcomes in septic patients","volume":"85","author":"Liu","year":"2017","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0140","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143689","article-title":"Regulatory T cell responses to high-dose methylprednisolone in active systemic lupus erythematosus","volume":"10","author":"Mathian","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12967-016-1071-x","article-title":"Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS)","volume":"14","author":"Monaghan","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","article-title":"The soluble CTLA-4 receptor and its role in autoimmune diseases: an update","volume":"1","author":"Saverino","year":"2010","journal-title":"Auto. Immun. Highlights"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.immuni.2015.12.011","article-title":"Circulating HIV-specific Interleukin-21(+)CD4(+) T cells represent peripheral Tfh cells with antigen-dependent helper functions","volume":"44","author":"Schultz","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2004.04.019","article-title":"ICOS is essential for the development of experimental autoimmune myasthenia gravis","volume":"153","author":"Scott","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd4296","article-title":"Interleukin-21: a double-edged sword with therapeutic potential","volume":"13","author":"Spolski","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/icb.2013.68","article-title":"Follicular helper T-cell memory: establishing new frontiers during antibody response","volume":"92","author":"Tsai","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0180","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0185","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.4049\/jimmunol.177.12.8844","article-title":"Aberrant regulation of synovial T cell activation by soluble co-stimulatory molecules in rheumatoid arthritis","volume":"177","author":"Wan","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0165-5728(02)00228-X","article-title":"Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence","volume":"130","author":"Wang","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/sj.gene.6363816","article-title":"CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis","author":"Wang","year":"2002","journal-title":"Genes Immun."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0200","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.578014_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1508s100","article-title":"Experimental autoimmune myasthenia gravis in the mouse","author":"Wu","year":"2013","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0210","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/00207454.2020.1759587","article-title":"Suppression of the CD28\/B7 pathway reduces the occurrence and development of myasthenia gravis and cytokine levels","volume":"131","author":"Xue","year":"2021","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.7150\/ijms.18784","article-title":"Increase of soluble programmed cell death ligand 1 in patients with chronic hepatitis C","volume":"14","author":"Yamagiwa","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.jneuroim.2022.578014_bb0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clim.2019.07.011","article-title":"Unbalanced expression of membrane-bound and soluble inducible co-stimulator and programmed cell death 1 in patients with myasthenia gravis","volume":"207","author":"Yan","year":"2019","journal-title":"Clin. Immunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822002090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822002090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T01:26:56Z","timestamp":1675474016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572822002090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":44,"alternative-id":["S0165572822002090"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.578014","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.578014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"578014"}}